Identification

Name
Methsuximide
Accession Number
DB05246
Type
Small Molecule
Groups
Approved
Description

Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin. [Wikipedia]

Structure
Thumb
Synonyms
  • (RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion
  • 1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine
  • 1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione
  • 1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione
  • 1,3-Dimethyl-3-phenylsuccinimide
  • Alpha-methyl-alpha-phenyl n-methyl succinimide
  • Alpha-methylphensuximide
  • Mesuximida
  • Mesuximide
  • Mesuximidum
  • Methsuximid
  • Metosuccimmide
  • Metsuccimide
  • N-methyl-alpha-methyl-alpha-phenylsuccinimide
  • N,2-Dimethyl-2-phenylsuccinimide
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CelontinCapsule300 mg/1OralParke Davis Div Of Pfizer Inc1957-02-08Not applicableUs
Celontin Cap 300mgCapsule300 mgOralErfa Canada 2012 Inc1957-12-312015-06-05Canada
International/Other Brands
Celontin / Petinutin
Categories
UNII
0G76K8X6C0
CAS number
77-41-8
Weight
Average: 203.2371
Monoisotopic: 203.094628665
Chemical Formula
C12H13NO2
InChI Key
AJXPJJZHWIXJCJ-UHFFFAOYSA-N
InChI
InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3
IUPAC Name
1,3-dimethyl-3-phenylpyrrolidine-2,5-dione
SMILES
CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1

Pharmacology

Indication

For the control of absence (petit mal) seizures that are refractory to other drugs.

Associated Conditions
Pharmacodynamics

Used in the treatment of epilepsy. Methsuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.

Mechanism of action

Binds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.

TargetActionsOrganism
AVoltage-dependent T-type calcium channel subunit alpha-1G
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

1.4-2.6 hours for mesuximide and 28-38 hours for the active metabolite.

Clearance
Not Available
Toxicity

Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression. Levels greater than 40 µg/mL have caused toxicity and coma has been seen at levels of 150 µg/mL.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3-isobutyl-1-methyl-7H-xanthineMethsuximide may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
6-O-benzylguanineMethsuximide may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
7-DeazaguanineMethsuximide may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Methsuximide is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
7,9-DimethylguanineMethsuximide may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
8-azaguanineMethsuximide may increase the excretion rate of 8-azaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
8-chlorotheophyllineMethsuximide may increase the excretion rate of 8-chlorotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
9-DeazaguanineMethsuximide may increase the excretion rate of 9-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
9-MethylguanineMethsuximide may increase the excretion rate of 9-Methylguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Methsuximide.Investigational
AbirateroneThe metabolism of Methsuximide can be decreased when combined with Abiraterone.Approved
AcefyllineMethsuximide may increase the excretion rate of Acefylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Methsuximide.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Acetylglycinamide chloral hydrate.Experimental
AcyclovirMethsuximide may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Methsuximide is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Alaproclate.Experimental
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Methsuximide.Investigational
AlcuroniumMethsuximide may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methsuximide.Approved, Illicit
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Methsuximide.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Methsuximide is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Methsuximide is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methsuximide.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Methsuximide is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Alverine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Amineptine.Illicit, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Methsuximide.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Amitriptylinoxide.Approved, Investigational
AmobarbitalThe metabolism of Methsuximide can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Methsuximide.Approved
AmperozideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Amphetamine.Approved, Illicit, Investigational
Amphotericin BMethsuximide may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Aniracetam.Experimental
ApalutamideThe serum concentration of Methsuximide can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Methsuximide is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Apramycin.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Methsuximide is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Arbekacin.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Methsuximide.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Methsuximide.Approved, Investigational
ArmodafinilThe metabolism of Methsuximide can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Methsuximide.Investigational
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Methsuximide.Approved
AtomoxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Atomoxetine.Approved
AtracuriumMethsuximide may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateMethsuximide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Azaperone.Investigational, Vet Approved
AzathioprineMethsuximide may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.Approved
AZD-3043The risk or severity of adverse effects can be increased when Methsuximide is combined with AZD-3043.Investigational
AzelastineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Methsuximide.Approved
BamifyllineMethsuximide may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BarbexacloneThe metabolism of Methsuximide can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Methsuximide can be increased when combined with Barbital.Illicit
BeclamideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Beclamide.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Benactyzine.Withdrawn
BenmoxinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Benperidol.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Benzoctamine.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Methsuximide is combined with Benzyl alcohol.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Methsuximide.Approved
BifemelaneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Methsuximide is combined with Bifeprunox.Investigational
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Methsuximide.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Methsuximide.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Methsuximide.Approved
BL-1020The risk or severity of adverse effects can be increased when Methsuximide is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Blonanserin.Approved, Investigational
BortezomibThe metabolism of Methsuximide can be decreased when combined with Bortezomib.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Methsuximide is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Methsuximide is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Methsuximide.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methsuximide.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Methsuximide.Approved, Investigational
BromotheophyllineMethsuximide may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
BromperidolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Methsuximide.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Methsuximide.Investigational
BufotenineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Bufotenine.Experimental, Illicit
BufyllineMethsuximide may increase the excretion rate of Bufylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Methsuximide.Investigational
BuprenorphineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Methsuximide is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methsuximide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methsuximide.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Methsuximide.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Butethal.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Methsuximide.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methsuximide.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Butriptyline.Approved
CabergolineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cabergoline.Approved
CafedrineMethsuximide may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
CaffeineMethsuximide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.Approved
Calcium AcetateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Phosphate.Approved
CamazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Camazepam.Approved, Illicit
CannabidiolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Methsuximide is combined with Captodiame.Approved, Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methsuximide.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Methsuximide.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Methsuximide.Approved, Investigational
CarbromalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Methsuximide is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methsuximide.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Caroxazone.Withdrawn
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Methsuximide.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Methsuximide.Approved, Investigational, Nutraceutical, Vet Approved
CathinoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cathinone.Illicit
CerlapirdineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methsuximide.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Methsuximide can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methsuximide.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methsuximide.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Methsuximide.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methsuximide.Approved
CilansetronThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cilansetron.Investigational
CimetidineThe serum concentration of Methsuximide can be increased when it is combined with Cimetidine.Approved, Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cinolazepam.Approved
CisaprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumMethsuximide may increase the neuromuscular blocking activities of Cisatracurium.Approved
CitalopramThe risk or severity of adverse effects can be increased when Methsuximide is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Methsuximide.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Methsuximide.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Methsuximide.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Methsuximide can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Methsuximide.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Methsuximide.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Methsuximide.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methsuximide.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Methsuximide.Approved, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Methsuximide.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methsuximide.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Colistin.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Methsuximide.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methsuximide.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Methsuximide.Approved
DabrafenibThe serum concentration of Methsuximide can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Methsuximide.Approved, Investigational, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Methsuximide.Approved, Investigational
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Methsuximide.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dapoxetine.Investigational
DeanolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Deanol.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Methsuximide is combined with Decamethonium.Approved
DelavirdineThe metabolism of Methsuximide can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methsuximide.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Methsuximide.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methsuximide.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methsuximide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dextofisopam.Investigational
DextromethorphanThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methsuximide.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dichloralphenazone.Approved, Illicit
Diethyl etherThe risk or severity of adverse effects can be increased when Methsuximide is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Methsuximide.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methsuximide.Approved, Illicit
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Methsuximide.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dihydrostreptomycin.Investigational, Vet Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methsuximide.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dimethyltryptamine.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methsuximide.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methsuximide.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dixyrazine.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Methsuximide.Approved
DolasetronThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Methsuximide is combined with Domoic Acid.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Methsuximide is combined with Donepezil.Approved
DopamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Doramectin.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dotarizine.Investigational
DoxacuriumMethsuximide may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Methsuximide.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Methsuximide.Approved, Investigational
DoxofyllineMethsuximide may increase the excretion rate of Doxofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Methsuximide is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Illicit
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Methsuximide.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dyclonine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Methsuximide.Approved
EcopipamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Edivoxetine.Investigational
EfavirenzThe serum concentration of Methsuximide can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Methsuximide.Approved
EletriptanThe risk or severity of adverse effects can be increased when Methsuximide is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Eltoprazine.Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Methsuximide is combined with Emepronium.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Methsuximide.Approved, Investigational
EntecavirMethsuximide may increase the excretion rate of Entecavir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Epinastine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ergonovine.Approved
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Methsuximide.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Methsuximide is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Esmirtazapine.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Methsuximide.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methsuximide.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etacrynic acid.Approved, Investigational
EtamiphyllineMethsuximide may increase the excretion rate of Etamiphylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ethadione.Experimental
EthanolMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methsuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Methsuximide.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Methsuximide.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fabomotizole.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Methsuximide.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenethyllineMethsuximide may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
FenfluramineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methsuximide.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Methsuximide.Experimental
FenyramidolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fenyramidol.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Methsuximide.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Methsuximide.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Methsuximide can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methsuximide.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Methsuximide.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methsuximide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methsuximide.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Methsuximide.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Methsuximide.Experimental
FluvoxamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Methsuximide.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Methsuximide is combined with Frovatriptan.Approved, Investigational
FurafyllineMethsuximide may increase the excretion rate of Furafylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
FurazolidoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Furazolidone.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methsuximide.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Methsuximide is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Gaboxadol.Investigational
GallamineMethsuximide may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideMethsuximide may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Methsuximide.Approved, Illicit, Investigational
GanciclovirMethsuximide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Methsuximide is combined with Gedocarnil.Experimental
GemfibrozilThe metabolism of Methsuximide can be decreased when combined with Gemfibrozil.Approved
GeneticinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Methsuximide is combined with GENTAMICIN C1A.Experimental
GepironeThe risk or severity of adverse effects can be increased when Methsuximide is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Glutethimide.Approved, Illicit
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Methsuximide.Approved, Investigational
GranisetronThe risk or severity of adverse effects can be increased when Methsuximide is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methsuximide.Approved, Investigational
GuanineMethsuximide may increase the excretion rate of Guanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methsuximide.Approved
HalothaneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Methsuximide is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Methsuximide is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Hexapropymate.Experimental
HexobarbitalThe metabolism of Methsuximide can be increased when combined with Hexobarbital.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Hydracarbazine.Experimental
HydrocodoneMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methsuximide.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Methsuximide is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Hypericin.Investigational
HypoxanthineMethsuximide may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
IdalopirdineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Idalopirdine.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Methsuximide.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Imagabalin.Investigational
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Methsuximide.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Imipramine oxide.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Methsuximide is combined with Indiplon.Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Methsuximide.Withdrawn
IprazochromeThe risk or severity of adverse effects can be increased when Methsuximide is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Methsuximide is combined with Iproniazid.Withdrawn
IsavuconazoleThe therapeutic efficacy of Isavuconazole can be increased when used in combination with Methsuximide.Approved, Investigational
IsavuconazoniumThe therapeutic efficacy of Isavuconazonium can be increased when used in combination with Methsuximide.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Methsuximide is combined with Isocarboxazid.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Methsuximide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methsuximide.Approved, Vet Approved
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Methsuximide.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methsuximide.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Methsuximide.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when Methsuximide is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Methsuximide.Approved
LacosamideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lacosamide.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Methsuximide.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Methsuximide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methsuximide.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lanicemine.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lasmiditan.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methsuximide.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Methsuximide.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methsuximide.Approved
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Methsuximide.Approved
LincomycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Methsuximide is combined with Linezolid.Approved, Investigational
LisofyllineMethsuximide may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
LisurideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lithium cation.Experimental
LobucavirMethsuximide may increase the excretion rate of Lobucavir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Methsuximide can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Methsuximide.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methsuximide.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lormetazepam.Approved
LorpiprazoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lortalamine.Experimental
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methsuximide.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Methsuximide.Approved, Investigational
LuliconazoleThe serum concentration of Methsuximide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Methsuximide can be decreased when it is combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lumateperone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methsuximide.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Methsuximide is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Methsuximide is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Methsuximide.Experimental
Magnesium phosphateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium phosphate.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Methsuximide is combined with Magnesium salicylate.Approved
Magnesium silicateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Methsuximide can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium Trisilicate.Approved
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Methsuximide.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methsuximide.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Methsuximide is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Methsuximide.Approved
MedazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Medifoxamine.Experimental
MefloquineThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Methsuximide is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Methsuximide is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Melperone.Approved, Investigational
MephenesinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Mephenoxalone.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Mephenytoin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methsuximide.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methsuximide.Approved
MetergolineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methsuximide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methsuximide.Approved, Vet Approved
MethohexitalThe metabolism of Methsuximide can be increased when combined with Methohexital.Approved
MethotrimeprazineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methoxyflurane.Approved, Investigational, Vet Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Methsuximide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe metabolism of Methsuximide can be increased when combined with Methylphenobarbital.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methysergide.Approved
MetocurineMethsuximide may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideMethsuximide may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetyrosineMethsuximide may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Mianserin.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Methsuximide.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methsuximide.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Methsuximide is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Minaprine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Methsuximide.Approved, Vet Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Investigational
MirtazapineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumMethsuximide may increase the neuromuscular blocking activities of Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Methsuximide is combined with MK-212.Investigational
MMDAThe risk or severity of adverse effects can be increased when Methsuximide is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Methsuximide can be decreased when combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methsuximide.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when Methsuximide is combined with MRK-409.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Investigational
NafcillinThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Methsuximide is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methsuximide.Approved
NaluzotanThe risk or severity of adverse effects can be increased when Methsuximide is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Methsuximide is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Nefiracetam.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Methsuximide is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Neosaxitoxin.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Netilmicin.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Niaprazine.Experimental
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Methsuximide.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Methsuximide.Approved, Investigational
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Methsuximide.Experimental
NisoxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methsuximide.Approved
NitroprussideMethsuximide may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Methsuximide.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Nordazepam.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Methsuximide.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Methsuximide.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methsuximide.Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Methsuximide.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Methsuximide is combined with Opium.Approved, Illicit
OrlistatOrlistat can cause a decrease in the absorption of Methsuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OrphenadrineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Methsuximide is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Methsuximide is combined with Osanetant.Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Oxaflozane.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Oxaprotiline.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methsuximide.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Oxcarbazepine.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Methsuximide.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Methsuximide is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxprenololThe risk or severity of adverse effects can be increased when Methsuximide is combined with Oxprenolol.Approved
OxtriphyllineMethsuximide may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methsuximide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methsuximide.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Oxypertine.Experimental
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Methsuximide.Investigational, Withdrawn
OxytetracyclineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Methsuximide.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Methsuximide is combined with Palonosetron.Approved, Investigational
PancuroniumMethsuximide may increase the neuromuscular blocking activities of Pancuronium.Approved
ParaldehydeMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Paramethadione.Approved
PargylineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Paroxetine.Approved, Investigational
PeldesineMethsuximide may increase the excretion rate of Peldesine which could result in a lower serum level and potentially a reduction in efficacy.Experimental, Investigational
PemetrexedMethsuximide may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Methsuximide is combined with Penbutolol.Approved, Investigational
PenciclovirMethsuximide may increase the excretion rate of Penciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Penimepicycline.Experimental
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Methsuximide.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methsuximide.Approved, Vet Approved
PentifyllineMethsuximide may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PentobarbitalThe metabolism of Methsuximide can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllineMethsuximide may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
PerazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Perazine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Methsuximide is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methsuximide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methsuximide.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pheneturide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Methsuximide can be increased when combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Methsuximide.Approved, Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Methsuximide.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phensuximide.Approved
PhentermineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phentermine.Approved, Illicit
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Methsuximide.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Methsuximide.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when Methsuximide is combined with Piclozotan.Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Methsuximide.Approved
PimavanserinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methsuximide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pinazepam.Experimental
PindololThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pipamperone.Approved, Investigational
PipecuroniumMethsuximide may increase the neuromuscular blocking activities of Pipecuronium.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methsuximide.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pirlindole.Approved
PivagabineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Methsuximide.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Methsuximide.Approved, Investigational
PlazomicinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Plazomicin.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Methsuximide.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Methsuximide.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methsuximide.Approved, Vet Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pomalidomide.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Methsuximide.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Methsuximide.Approved, Investigational
PramipexoleMethsuximide may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Methsuximide.Approved
PregabalinThe therapeutic efficacy of Methsuximide can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pridinol.Experimental
PrimidoneThe metabolism of Methsuximide can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methsuximide.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Progabide.Approved, Investigational
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Methsuximide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Methsuximide.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Methsuximide is combined with Propanidid.Experimental
PropentofyllineMethsuximide may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Methsuximide.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Methsuximide.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Propiopromazine.Vet Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Methsuximide.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methsuximide.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Methsuximide is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methsuximide.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Proxibarbal.Experimental
ProxyphyllineMethsuximide may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Methsuximide.Approved
PRX-08066The risk or severity of adverse effects can be increased when Methsuximide is combined with PRX-08066.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pseudoephedrine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Methsuximide.Approved, Illicit
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Methsuximide.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Methsuximide.Approved, Investigational
QuinineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ramosetron.Approved, Investigational
RapacuroniumMethsuximide may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Rasagiline.Approved
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Methsuximide.Investigational
ReboxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Reboxetine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methsuximide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Methsuximide is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methsuximide.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ribostamycin.Approved, Investigational
RifampicinThe metabolism of Methsuximide can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Methsuximide can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Methsuximide can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Methsuximide can be increased when combined with Rifaximin.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with Riluzole.Approved, Investigational
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Methsuximide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ritanserin.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Methsuximide is combined with Rizatriptan.Approved
RocuroniumMethsuximide may increase the neuromuscular blocking activities of Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when Methsuximide is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Romifidine.Vet Approved
RopiniroleMethsuximide may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineMethsuximide may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Methsuximide is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methsuximide.Approved
SafinamideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Safrazine.Withdrawn
SaredutantThe risk or severity of adverse effects can be increased when Methsuximide is combined with Saredutant.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methsuximide.Approved, Investigational
SecobarbitalThe metabolism of Methsuximide can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Selegiline.Approved, Investigational, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Methsuximide.Approved
SerotoninThe risk or severity of adverse effects can be increased when Methsuximide is combined with Serotonin.Investigational, Nutraceutical
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Methsuximide.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methsuximide.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Methsuximide.Approved
SisomicinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sisomicin.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Methsuximide.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Methsuximide.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Methsuximide.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Methsuximide.Approved
St. John's WortThe risk or severity of adverse effects can be increased when Methsuximide is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe metabolism of Methsuximide can be decreased when combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methsuximide.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Methsuximide.Approved
SulpirideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sumatriptan.Approved, Investigational
SuvorexantMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Talbutal.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Methsuximide is combined with Talopram.Experimental
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Methsuximide.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Methsuximide is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tegaserod.Approved, Investigational, Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methsuximide.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Methsuximide.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Methsuximide.Approved
TetracyclineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tetrodotoxin.Investigational
ThalidomideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineMethsuximide may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
TheodrenalineMethsuximide may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
ThiamylalThe metabolism of Methsuximide can be increased when combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe metabolism of Methsuximide can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Methsuximide.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Methsuximide.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methsuximide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Methsuximide.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Methsuximide can be decreased when combined with Ticlopidine.Approved
TigecyclineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tilidine.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Methsuximide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methsuximide.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tobramycin.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tofisopam.Approved
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Methsuximide.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methsuximide.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tolperisone.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Methsuximide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methsuximide.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methsuximide.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Methsuximide is combined with Triclofos.Withdrawn
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Methsuximide.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Triflupromazine.Approved, Vet Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Methsuximide.Experimental
TrimethadioneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Trimethadione.Approved
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Methsuximide.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Methsuximide.Approved
TropisetronThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tropisetron.Approved, Investigational
TubocurarineMethsuximide may increase the neuromuscular blocking activities of Tubocurarine.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Methsuximide.Investigational
Uric AcidMethsuximide may increase the excretion rate of Uric Acid which could result in a lower serum level and potentially a reduction in efficacy.Experimental, Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vabicaserin.Investigational
ValaciclovirMethsuximide may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValerianThe risk or severity of adverse effects can be increased when Methsuximide is combined with Valerian.Approved, Experimental, Investigational
ValganciclovirMethsuximide may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Valnoctamide.Investigational
ValomaciclovirMethsuximide may increase the excretion rate of Valomaciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Methsuximide is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vancomycin.Approved
VecuroniumMethsuximide may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Methsuximide.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Veralipride.Experimental
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Methsuximide.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Methsuximide.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vinylbital.Experimental
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Methsuximide.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vortioxetine.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Methsuximide is combined with Wortmannin.Experimental
XanthineMethsuximide may increase the excretion rate of Xanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
XP19986The risk or severity of adverse effects can be increased when Methsuximide is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Methsuximide is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methsuximide.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Methsuximide.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Methsuximide is combined with Zolmitriptan.Approved, Investigational
ZolpidemMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methsuximide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Methsuximide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Methsuximide can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Methsuximide.Approved, Investigational
Food Interactions
  • Avoid alcohol
  • Take with food

References

General References
  1. Hurst DL: Methsuximide therapy of juvenile myoclonic epilepsy. Seizure. 1996 Mar;5(1):47-50. [PubMed:8777552]
  2. Besag FM, Berry DJ, Pool F: Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction. Epilepsia. 2000 May;41(5):624-7. [PubMed:10802770]
External Links
Human Metabolome Database
HMDB0015611
PubChem Compound
6476
PubChem Substance
46505339
ChemSpider
6231
ChEBI
6846
ChEMBL
CHEMBL697
Therapeutic Targets Database
DAP001253
PharmGKB
PA164743145
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Methsuximide
ATC Codes
N03AD03 — Mesuximide

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Farmea
  • Kaiser Foundation Hospital
  • Pfizer Inc.
Dosage forms
FormRouteStrength
CapsuleOral300 mg/1
CapsuleOral300 mg
Prices
Unit descriptionCostUnit
Celontin 300 mg kapseal1.53USD each
Celontin 300 mg Capsule1.1USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)52.5 °CPhysProp
boiling point (°C)121.5 °C at 1.00E-01 mm HgPhysProp
Predicted Properties
PropertyValueSource
Water Solubility2.13 mg/mLALOGPS
logP1.46ALOGPS
logP1.46ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)19.03ChemAxon
pKa (Strongest Basic)-7.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area37.38 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity56.35 m3·mol-1ChemAxon
Polarizability21.4 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9967
Caco-2 permeable+0.6968
P-glycoprotein substrateNon-substrate0.7118
P-glycoprotein inhibitor INon-inhibitor0.8599
P-glycoprotein inhibitor IINon-inhibitor0.9433
Renal organic cation transporterNon-inhibitor0.7784
CYP450 2C9 substrateNon-substrate0.7943
CYP450 2D6 substrateNon-substrate0.8923
CYP450 3A4 substrateSubstrate0.6004
CYP450 1A2 substrateNon-inhibitor0.888
CYP450 2C9 inhibitorNon-inhibitor0.8882
CYP450 2D6 inhibitorNon-inhibitor0.922
CYP450 2C19 inhibitorNon-inhibitor0.845
CYP450 3A4 inhibitorNon-inhibitor0.9748
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9629
Ames testNon AMES toxic0.9099
CarcinogenicityNon-carcinogens0.8355
BiodegradationNot ready biodegradable0.8265
Rat acute toxicity2.1961 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9942
hERG inhibition (predictor II)Non-inhibitor0.9625
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-014i-3910000000-9cae394b5b94a483c401
GC-MS Spectrum - CI-BGC-MSsplash10-0udi-0090000000-31b6e0b0429306f0d6da
GC-MS Spectrum - CI-BGC-MSsplash10-0udi-0490000000-37eb2b7cfbb3d8b42e97
Mass Spectrum (Electron Ionization)MSsplash10-014i-4910000000-aa3742fc04cdbcda351f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0390000000-00d729cf9e85b7d75068
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-1690000000-0a263ad37a0831b81fb3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-4910000000-eb0a383017c0566e6a11
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-9800000000-5df2aae06682d9488eef
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05mo-9400000000-6de622fc3efce00a0b34
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052f-9300000000-1e2faae8b516a3fc7ad5

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpyrrolidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrolidine ring through a CC or CN bond. Pyrrolidine is a five-membered saturated aliphatic heterocycle with one nitrogen atom and four carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrrolidines
Sub Class
Phenylpyrrolidines
Direct Parent
Phenylpyrrolidines
Alternative Parents
Pyrrolidine-2-ones / N-substituted carboxylic acid imides / N-alkylpyrrolidines / Benzene and substituted derivatives / Pyrroles / Dicarboximides / Lactams / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 3 more
Substituents
3-phenylpyrrolidine / Monocyclic benzene moiety / Carboxylic acid imide, n-substituted / Pyrrolidone / 2-pyrrolidone / N-alkylpyrrolidine / Benzenoid / Carboxylic acid imide / Dicarboximide / Pyrrole
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1G
Uniprot ID
O43497
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1G
Molecular Weight
262468.62 Da
References
  1. Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E: Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32. [PubMed:11641441]
  2. Coulter DA, Huguenard JR, Prince DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989 Jun;25(6):582-93. [PubMed:2545161]
  3. Wang G, Thompson SM: Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69. doi: 10.1523/JNEUROSCI.3296-08.2008. [PubMed:19005061]
  4. Matthews EA, Dickenson AH: Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol. 2001 Mar;415(2-3):141-9. [PubMed:11274992]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on October 30, 2007 19:03 / Updated on August 02, 2018 05:30